Biology:hERG

From HandWiki
Revision as of 15:35, 12 February 2024 by Dennis Ross (talk | contribs) (add)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Mammalian protein found in humans

A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

hERG (the human Ether-à-go-go-Related Gene) is a gene (KCNH2) that codes for a protein known as Kv11.1, the alpha subunit of a potassium ion channel. This ion channel (sometimes simply denoted as 'hERG') is best known for its contribution to the electrical activity of the heart: the hERG channel mediates the repolarizing IKr current in the cardiac action potential, which helps coordinate the heart's beating.

When this channel's ability to conduct electrical current across the cell membrane is inhibited or compromised, either by application of drugs or by rare mutations in some families,[1] it can result in a potentially fatal disorder called long QT syndrome. Conversely, genetic mutations that increase the current through these channels can lead to the related inherited heart rhythm disorder Short QT syndrome.[2] A number of clinically successful drugs in the market have had the tendency to inhibit hERG, lengthening the QT and potentially leading to a fatal irregularity of the heartbeat (a ventricular tachyarrhythmia called torsades de pointes). This has made hERG inhibition an important antitarget that must be avoided during drug development.[3]

hERG has also been associated with modulating the functions of some cells of the nervous system[4][5] and with establishing and maintaining cancer-like features in leukemic cells.[6]

Function

hERG forms the major portion of one of the ion channel proteins (the 'rapid' delayed rectifier current (IKr)) that conducts potassium (K+) ions out of the muscle cells of the heart (cardiac myocytes), and this current is critical in correctly timing the return to the resting state (repolarization) of the cell membrane during the cardiac action potential.[3] Sometimes, when referring to the pharmacological effects of drugs, the terms "hERG channels" and IKr are used interchangeably, but, in the technical sense, "hERG channels" can be made only by scientists in the laboratory; in formal terms, the naturally occurring channels in the body that include hERG are referred to by the name of the electrical current that has been measured in that cell type, so, for example, in the heart, the correct name is IKr. This difference in nomenclature becomes clearer in the controversy as to whether the channels conducting IKr include other subunits (e.g., beta subunits[7][8][9]) or whether the channels include a mixture of different types (isoforms) of hERG,[10][11] but, when the originally-discovered form of hERG[12][13][14] is experimentally transferred into cells that previously lacked hERG (i.e., heterologous expression), a potassium ion channel is formed, and this channel has many signature features of the cardiac 'rapid' delayed rectifier current (IKr),[14][13][11] including IKr's inward rectification that results in the channel producing a 'paradoxical resurgent current' in response to repolarization of the membrane.[15]

Structure

A detailed atomic structure for hERG based on X-ray crystallography is not yet available, but structures have recently been solved by electron microscopy.[16] In the laboratory the heterologously expressed hERG potassium channel comprises 4 identical alpha subunits, which form the channel's pore through the plasma membrane. Each hERG subunit consists of 6 transmembrane alpha helices, numbered S1-S6, a pore helix situated between S5 and S6, and cytoplasmically located N- and C-termini. The S4 helix contains a positively charged arginine or lysine amino acid residue at every 3rd position and is thought to act as a voltage-sensitive sensor, which allows the channel to respond to voltage changes by changing conformations between conducting and non-conducting states (called 'gating'). Between the S5 and S6 helices, there is an extracellular loop (known as 'the turret') and 'the pore loop', which begins and ends extracellularly but loops into the plasma membrane; the pore loop for each of the hERG subunits in one channel faces into the ion-conducting pore and is adjacent to the corresponding loops of the 3 other subunits, and together they form the selectivity filter region of the channel pore. The selectivity sequence, SVGFG, is very similar to that contained in bacterial KcsA channels.[3] Although a full crystal structure for hERG is not yet available, a structure has been found for the cytoplasmic N-terminus, which was shown to contain a PAS domain (aminoacid 26–135) that slows the rate of deactivation.[17]

Genetics

Loss-of-function mutations in this channel may lead to long QT syndrome (LQT2), while gain-of-function mutations may lead to short QT syndrome. Both clinical disorders stem from ion channel dysfunction (so-called channelopathies) that can lead to the risk of potentially fatal cardiac arrhythmias (e.g., torsades de pointes), due to repolarization disturbances of the cardiac action potential.[14][18] There are far more hERG mutations described for long QT syndrome than for short QT syndrome.[1]

Drug interactions

This channel is also sensitive to drug binding, as well as decreased extracellular potassium levels, both of which can result in decreased channel function and drug-induced (acquired) long QT syndrome. Among the drugs that can cause QT prolongation, the more common ones include antiarrhythmics (especially Class 1A and Class III), anti-psychotic agents, and certain antibiotics (including quinolones and macrolides).[3]

Although there exist other potential targets for cardiac adverse effects, the vast majority of drugs associated with acquired QT prolongation are known to interact with the hERG potassium channel. One of the main reasons for this phenomenon is the larger inner vestibule of the hERG channel, thus providing more space for many different drug classes to bind and block this potassium channel.[19]

hERG containing channels are blocked by amiodarone, and it does prolong the QT interval, but its multiple other antiarrhythmic effects prevent this from causing torsades de pointes.[20]

Thioridazine causes peculiarly severe QTc prolongation by blocking hERG and was withdrawn by the manufacturer for this reason.

Drug development considerations

Due to the documented potential of QT-interval-prolonging drugs, the United States Food and Drug Administration issued recommendations for the establishment of a cardiac safety profile during pre-clinical drug development: ICH S7B.[21] The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals, issued as CHMP/ICH/423/02, adopted by CHMP in May 2005. Preclinical hERG studies should be accomplished in GLP environment.

Naming

The hERG gene was first named and described in a paper by Jeff Warmke and Barry Ganetzky, then both at the University of Wisconsin–Madison.[12] The hERG gene is the human homolog of the Ether-à-go-go gene found in the Drosophila fly; Ether-à-go-go was named in the 1960s by William D. Kaplan and William E. Trout, III, while at the City of Hope Hospital in Duarte, California. When flies with mutations in the Ether-à-go-go gene are anaesthetised with ether, their legs start to shake, like the dancing at the then popular Whisky a Go Go nightclub in West Hollywood, California.[22]

Interactions

HERG has been shown to interact with the 14-3-3 epsilon protein, encoded by YWHAE.[23]

See also

References

  1. ↑ 1.0 1.1 "The genetic basis of long QT and short QT syndromes: a mutation update". Human Mutation 30 (11): 1486–1511. November 2009. doi:10.1002/humu.21106. PMID 19862833. 
  2. ↑ "Diagnosis and management of short QT syndrome". Heart Rhythm 15 (8): 1261–1267. August 2018. doi:10.1016/j.hrthm.2018.02.034. PMID 29501667. 
  3. ↑ 3.0 3.1 3.2 3.3 "hERG potassium channels and cardiac arrhythmia". Nature 440 (7083): 463–469. March 2006. doi:10.1038/nature04710. PMID 16554806. Bibcode: 2006Natur.440..463S. 
  4. ↑ "A novel role for HERG K+ channels: spike-frequency adaptation". The Journal of Physiology 501 ( Pt 2) (Pt 2): 313–318. June 1997. doi:10.1111/j.1469-7793.1997.313bn.x. PMID 9192303. 
  5. ↑ Chemosensing at the carotid body. Involvement of a HERG-like potassium current in glomus cells. Advances in Experimental Medicine and Biology. 475. 2002. pp. 241–248. doi:10.1007/0-306-46825-5_22. ISBN 978-0-306-46367-9. 
  6. ↑ The hERG Cardiac Potassium Channel: Structure, Function and Long QT Syndrome. Novartis Foundation Symposia. 266. 2005. pp. 225–32; discussion 232–4. doi:10.1002/047002142X.ch17. ISBN 9780470021408. 
  7. ↑ "A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?". The Journal of Physiology 540 (Pt 1): 15–27. April 2002. doi:10.1113/jphysiol.2001.013296. PMID 11927665. 
  8. ↑ "Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism". FASEB Journal 16 (3): 390–400. March 2002. doi:10.1096/fj.01-0520hyp. PMID 11874988. https://escholarship.org/uc/item/99v7r735. 
  9. ↑ "MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia". Cell 97 (2): 175–187. April 1999. doi:10.1016/S0092-8674(00)80728-X. PMID 10219239. 
  10. ↑ "Cardiac IKr channels minimally comprise hERG 1a and 1b subunits". The Journal of Biological Chemistry 279 (43): 44690–44694. October 2004. doi:10.1074/jbc.M408344200. PMID 15304481. 
  11. ↑ 11.0 11.1 Gating and assembly of heteromeric hERG1a/1b channels underlying I(Kr) in the heart. Novartis Foundation Symposia. 266. 2005. 4–15; discussion 15–8, 44–5. doi:10.1002/047002142X.ch2. ISBN 9780470021408. 
  12. ↑ 12.0 12.1 "A family of potassium channel genes related to eag in Drosophila and mammals". Proceedings of the National Academy of Sciences of the United States of America 91 (8): 3438–3442. April 1994. doi:10.1073/pnas.91.8.3438. PMID 8159766. Bibcode: 1994PNAS...91.3438W. 
  13. ↑ 13.0 13.1 "HERG, a human inward rectifier in the voltage-gated potassium channel family". Science 269 (5220): 92–95. July 1995. doi:10.1126/science.7604285. PMID 7604285. Bibcode: 1995Sci...269...92T. 
  14. ↑ 14.0 14.1 14.2 "A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel". Cell 81 (2): 299–307. April 1995. doi:10.1016/0092-8674(95)90340-2. PMID 7736582. 
  15. ↑ "LQT2 : amplitude reduction and loss of selectivity in the tail that wags the HERG channel". Circulation Research 86 (5): 492–493. March 2000. doi:10.1161/01.res.86.5.492. PMID 10720408. 
  16. ↑ "Cryo-EM Structure of the Open Human Ether-à-go-go-Related K+ Channel hERG". Cell 169 (3): 422–430.e10. April 2017. doi:10.1016/j.cell.2017.03.048. PMID 28431243. 
  17. ↑ "Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain". Cell 95 (5): 649–655. November 1998. doi:10.1016/S0092-8674(00)81635-9. PMID 9845367. 
  18. ↑ "Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel". Circulation 105 (7): 794–799. February 2002. doi:10.1161/hc0702.105124. PMID 11854117. 
  19. ↑ "Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652". British Journal of Pharmacology 139 (5): 887–898. July 2003. doi:10.1038/sj.bjp.0705335. PMID 12839862. 
  20. ↑ "Amiodarone". Drugbank. https://www.drugbank.ca/drugs/DB01118. 
  21. ↑ "S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals". 6 May 2020. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074963.pdf. 
  22. ↑ "The behavior of four neurological mutants of Drosophila". Genetics 61 (2): 399–409. February 1969. doi:10.1093/genetics/61.2.399. PMID 5807804. 
  23. ↑ "14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity". The EMBO Journal 21 (8): 1889–1898. April 2002. doi:10.1093/emboj/21.8.1889. PMID 11953308. 

Further reading

  • "The molecular genetics of the long QT syndrome: genes causing fainting and sudden death". Annual Review of Medicine 49: 263–274. 1998. doi:10.1146/annurev.med.49.1.263. PMID 9509262. 
  • "The long QT syndrome: ion channel diseases of the heart". Mayo Clinic Proceedings 73 (3): 250–269. March 1998. doi:10.4065/73.3.250. PMID 9511785. 
  • "Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications". Biochemical Pharmacology 55 (11): 1741–1746. June 1998. doi:10.1016/S0006-2952(98)00002-1. PMID 9714291. 
  • "Short QT syndrome: mechanisms, diagnosis and treatment". Nature Clinical Practice. Cardiovascular Medicine 2 (2): 84–87. February 2005. doi:10.1038/ncpcardio0097. PMID 16265378. 
  • "International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels". Pharmacological Reviews 57 (4): 473–508. December 2005. doi:10.1124/pr.57.4.10. PMID 16382104. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:HERG&oldid=3608028"